Latest
Pharm Exec's Emerging Pharma Leaders 2018
Pharm Exec’s 11th annual list profiles the diverse stories of 10 rising biopharma managers—and how each are changing the ways leaders direct critical industry functions.
Targeting the Affluent: Differential Access to Targeted Therapies in China
Disparities in income levels in China continue to drive far-reaching differences in how poorer and richer cancer patients are treated, with recent data suggesting different outcomes for poorer patients. Pieter De Richter reports.
Choosing the Right Track: Pharma & Healthcare MBAs
A growing range of MBAs with concentrations in pharmaceuticals and healthcare management are on offer. Pharm Exec look at how three of the top programs in the US prepare their students for industry success.
Social Science Behavior Change Models: The Key to More Targeted Messages
Charles Daramola discusses the application of social science behavior change theories and models to physician sales.
Pharm Exec Video
Behind the Scenes with Kallyope’s Nancy Thornberry
A sneak peek at Pharm Exec's August cover shoot with the New York City-based biotech CEO.
Why One Korean Biotech Picked New Jersey for U.S. Headquarters
New Jersey is still a top pick for companies when it comes to pharma.
Pharm Exec Talks Partnerships with Sanofi
Hear what Sanofi looks for when they decide to form a partnership with another company.
New & Noteworthy
Four Challenges Preventing AI Reaching Its Full Potential
AI has become ubiquitous in all industries, including life sciences. But is also attracting some concerns—around job losses, ethics, and more broadly, how successful it really is, writes Steve Arlington.
What the Age of Multi-Localism Means for Pharma
New realities are transforming the global environment and upending a business model based on the presumption of ever more connected markets. Paul A. Laudicina asks, What does this mean for pharma?
Managing Local Language Regulatory Submissions
Preparing products for distribution in international markets is far from straightforward. Nancy Pollini looks at what constitutes best practice in managing translations in today’s regulatory affairs environment.
Why Your Advertising Agency Should Be Your Analytics Partner
Brands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.
Sales & Marketing
Social Science Behavior Change Models: The Key to More Targeted Messages
Charles Daramola discusses the application of social science behavior change theories and models to physician sales.
Why Your Advertising Agency Should Be Your Analytics Partner
Brands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.
Learning, Retaining, Applying Information: Preparing Reps for Success in the Field
The most effective way to train sales reps and boost their success is to consider the learner/user experience in all facets, in every training encounter, and on each training platform, writes Shaun McMahon.
eBooks
Emerging BioPharma: Your Guide to Clinical and Commercial Considerations
This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways.
PEspeaks
Getting Where You Need to Go
As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.
Crash Course in Strategy
New life sciences internship program has high-level mission. Michelle Maskaly reports.
Vienna’s Vision on Health Regulation in Europe
What will come out of Austria’s shakeup of European pharma rules? Reflector reports.
Are the Right Drugs Getting Faster FDA Approval?
Leela Barham continues her series of features exploring expedited FDA approvals with a look at the therapy areas and the overlap with orphan drug designations.
Emerging Pharma Leaders
Interviews
The Path to Pioneership: Dr. J. Joseph Kim, Inovio Pharmaceuticals
Pharm Exec speaks to Inovio Pharmaceuticals' Dr. J. Joseph Kim about his journey from humble beginnings as an 11-year-old Korean immigrant to his present position at the forefront of a new medical frontier.
Paul Perreault: The Global CEO
Pharm Exec talks with CSL's top executive about the realities of running the global, Australian-headquartered specialty biotech company and sustaining a strong focus in a fast-encroaching era of disruptive technologies and new priorities in innovation and R&D.
Close to the Action: Dr. José Luis Cabero, CEO, AELIX Therapeutics
Pharm Exec talks to AELIX Therapeutics' Dr. José Luis Cabero about how the career and country shift he made a decade ago have motivated and sustained a new direction in his career.
Regulatory
Does Being an Orphan Speed Up FDA Approval?
Leela Barham looks at whether FDA approval is expedited when a drug not only secures one or more of the FDA’s expedited development and review methods, but is also when it is designated an orphan drug.
Big Companies Driving FDA Fast Lanes
Use of FDA's options for speedier approval applied to more than half of novel drug approvals in recent years. But which drugs–and from which companies–are being approved faster? Leela Barham reports.
Congressional Action Alters FDA Policies, Pharma Practices
Congress approves bills with provisions important to FDA and industry, some of which reflect continuing concerns about drug pricing and transparency.
Are the Right Drugs Getting Faster FDA Approval?
Leela Barham continues her series of features exploring expedited FDA approvals with a look at the therapy areas and the overlap with orphan drug designations.
From the Editor
Getting Where You Need to Go
As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.
Specialty Supply Chain Decisions
In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.
|
|---|
|
Sponsored Links
Global
Targeting the Affluent: Differential Access to Targeted Therapies in China
Disparities in income levels in China continue to drive far-reaching differences in how poorer and richer cancer patients are treated, with recent data suggesting different outcomes for poorer patients. Pieter De Richter reports.
Vienna’s Vision on Health Regulation in Europe
What will come out of Austria’s shakeup of European pharma rules? Reflector reports.
Managing Local Language Regulatory Submissions
Preparing products for distribution in international markets is far from straightforward. Nancy Pollini looks at what constitutes best practice in managing translations in today’s regulatory affairs environment.
Antibody-Drug Conjugates in China
In the face of the booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports.
The TKI Lung Cancer Market in China
Tyrosine-kinase inhibitors (TKIs) are gradually becoming the most popular option for lung cancer treatment in China. Jin Zhang reports.
Strategy
What the Age of Multi-Localism Means for Pharma
New realities are transforming the global environment and upending a business model based on the presumption of ever more connected markets. Paul A. Laudicina asks, What does this mean for pharma?
Specialty Product Launch Insights
Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.
Patent Research as a Key Strategy Tool
Paras Kumar examines the critical role that patent research has within life sciences beyond its traditional uses by the R&D and legal departments.
Technology
Four Challenges Preventing AI Reaching Its Full Potential
AI has become ubiquitous in all industries, including life sciences. But is also attracting some concerns—around job losses, ethics, and more broadly, how successful it really is, writes Steve Arlington.
Creating Defensible Data Analytics Moats for a Competitive Advantage
Karim Damji discusses how Artificial Intelligence (AI)-informed Systems of Intelligence and Virtual Assistants offer powerful solutions to the common struggles pharma companies face today.
Curing Big Pharma’s Litigation Spend Woes with Data-Driven Medicine
Daniel Gold looks at the benefits of centralizing an organization's data in a core repository and adopting a comprehensive business intelligence strategy.
